SciTegic Launches New Sequence Analysis Collection.

SAN DIEGO -- SciTegic, Inc., a wholly owned subsidiary of Accelrys, Inc. (NASDAQ:ACCL), is pleased to announce the release of the Sequence Analysis Collection for SciTegic's data pipelining software, Pipeline Pilot(TM), one of the leading data pipelining environment in discovery informatics.

With the Sequence Analysis Collection, it is now possible to analyze, annotate, and compare biological sequences in an environment where modular tools can be linked together effortlessly to create practical bioinformatics routines. SciTegic's pipelining platform has been well validated in other informatics disciplines, and has been deployed in cheminformatics for five years.

"This newest collection is only the first step towards supporting the expanding role of bioinformatics in the drug target validation process," said Mathew Hahn, Ph.D., vice president & general manager of SciTegic. "We have been very successful in helping our chemistry clients address real-world informatics challenges, and we will provide the same level of commitment to ensure the success of our customers in other life science domains."

While over fifty bioinformatics tools have been incorporated into the collection, the unique strength of the system is how easily customers can integrate additional in-house algorithms and third party software tools. For example, it is now possible to combine GCG(R) Wisconsin Package(TM) tools and open source software components quickly using the Pipeline Pilot informatics architecture.

"Pipeline Pilot software has enhanced our ability to integrate data from a variety of internal sources and has supported the automation of our processes, without the need to build custom software," said Michael R. Pear, Ph.D., director of Research Informatics at Isis Pharmaceuticals. "The new Sequence Analysis Collection allowed us to quickly apply Pipeline Pilot to our sequence-centric problems. The capabilities in Pipeline Pilot for integration, property calculation, and data flow have proven useful in cheminformatics and are now applicable to our bioinformatics processes."

About SciTegic

SciTegic, a wholly owned subsidiary of Accelrys, Inc. (NASDAQ:ACCL), develops and markets informatics software to the pharmaceutical and biotechnology industries. SciTegic has pioneered a technology approach called "Data Pipelining" to process drug discovery data with unprecedented flexibility. This methodology has established its utility by accelerating informatics research for thousands of users at hundreds of customer sites worldwide. Further information about SciTegic is available at: www.scitegic.com.

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). When used anywhere in this document, the words "expects," "believes," "anticipates," "estimates," and similar expressions are intended to identify forward-looking statements. Examples of such forward-looking statements herein include statements regarding the future success of the SciTegic Bioinformatics Sequence Analysis Collection. Accelrys and SciTegic have based these forward-looking statements on current expectations about future events. Such statements are subject to risks and uncertainties including, but not limited to, the successful implementation of Accelrys' strategic plans, the acceptance of new products, the obsolescence of existing products, the resolution of existing and potential future patent issues, additional competition, changes in economic conditions, and other risks and uncertainties described in documents Accelrys has filed with the Securities and Exchange Commission, including its most recent report on Form 10-Q. All forward-looking statements in this document are qualified entirely by the cautionary statements included in this document and such filings. These risks and uncertainties could cause actual results to differ materially from results expressed or implied by forward-looking statements contained in this document. These forward-looking statements speak only as of the date of this document. Accelrys claims the protection of the safe harbor for forward-looking statements contained in the Act, and disclaims any intent or obligation to publicly update or revise any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.